Finance

Lists
Why is GOVX down 16.42%?
Dive Deeper
GOVX:NASDAQ
GeoVax Labs Ord Shs
$1.70
-16.42%
(-0.33) 1D
$1.69
-0.88% (-0.015)
Pre-market
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GOVX...
Open
$2.20
High
$2.20
Low
$1.57
Mkt. cap
867.41K
Avg. vol.
54.29K
Volume
5.68M
52-wk high
$300.00
52-wk low
$1.57
EPS
-$157.85
Beta
3.85
Shares outstanding
544.00K
No. of employees
19
Open
$2.20
High
$2.20
Low
$1.57
Mkt. cap
867.41K
Avg. vol.
54.29K
Volume
5.68M
52-wk high
$300.00
52-wk low
$1.57
EPS
-$157.85
Beta
3.85
Shares outstanding
544.00K
No. of employees
19
News stories
From web sources and news partners
Profile
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated. Wikipedia
About GeoVax Labs Ord Shs
CEODavid A. Dodd
Employees19
Founded1988
HeadquartersAtlanta, Georgia, United States
SectorHealth Care
IndustryBiotechnology
Websitegeovax.com
Analyst ratings
Based on 1 analyst giving stock ratings to GOVX in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for GOVX in the last 3 months
Highest
Current $1.70
$240.00 (+13,976.25%)
Average
$240.00 (+13,976.25%)
Lowest
$240.00 (+13,976.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert LeBoyer
Noble Financial
Buy
Reiterated
$240.00
+13,976.2%
09/17/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
$10.00
+486.5%
05/26/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
02/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
2.99M
3.90M
3.11M
-
Cost of revenue
2.99M
3.90M
3.11M
-
Research and development expenses
-
-
-
2.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.45M
1.37M
1.33M
1.35M
Operating expense
1.45M
1.37M
1.33M
4.17M
Total operating expenses
4.44M
5.27M
4.44M
4.17M
Operating income
-4.44M
-5.27M
-4.44M
-4.17M
Other non operating income
-
-
-
-
EBT including unusual items
-4.42M
-5.26M
-4.43M
-4.16M
EBT excluding unusual items
-4.42M
-5.26M
-4.43M
-4.16M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.42M
-5.26M
-4.43M
-4.16M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
23.33K
10.96K
15.49K
18.47K
Interest expense
-
-
-
-
Net interest expenses
23.33K
10.96K
15.49K
18.47K
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.42M
-5.26M
-4.43M
-4.17M
Gain or loss from assets sale
-
-
-
58.58K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps